147 related articles for article (PubMed ID: 38687948)
1. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
Wu N; Yang X; Zhai Y; Lu W
J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
[TBL] [Abstract][Full Text] [Related]
4.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
Zhou M; Zhang X; Li T; Chen Y
J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
[TBL] [Abstract][Full Text] [Related]
6. Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report.
Xue W; Zhang T; Wang X; Duan J; Bi N
J Clin Pharm Ther; 2020 Dec; 45(6):1511-1514. PubMed ID: 32893899
[TBL] [Abstract][Full Text] [Related]
7. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
Zhang C; Yin K; Liu SY; Yan LX; Su J; Wu YL; Zhang XC; Zhong WZ; Yang XN
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820821
[TBL] [Abstract][Full Text] [Related]
8. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
9. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.
Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M
Lung Cancer; 2019 Jul; 133():4-9. PubMed ID: 31200826
[TBL] [Abstract][Full Text] [Related]
11. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
de Vries R; Muller M; van der Noort V; Theelen WSME; Schouten RD; Hummelink K; Muller SH; Wolf-Lansdorf M; Dagelet JWF; Monkhorst K; Maitland-van der Zee AH; Baas P; Sterk PJ; van den Heuvel MM
Ann Oncol; 2019 Oct; 30(10):1660-1666. PubMed ID: 31529107
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Yuan S; Hu X; Zhao Y; Wang Z
Front Immunol; 2020; 11():563622. PubMed ID: 33240259
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
20. A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.
Feng Y; Chen C; Zhao L; Zhu X; Zhu X; Li Q
BMC Pulm Med; 2021 Sep; 21(1):291. PubMed ID: 34521373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]